Table 1 Baseline characteristics of groups 1 & 2; risk factors, tumor characteristics, and treatment
Characteristic | Group 1 | Group 2 |
|---|---|---|
n = 101 | n = 22 | |
Age at diagnosis, | ||
(years); ±SD | 36.9 ± 5.2 | 53.1 ± 4.8 |
Familial cancer | ||
n (%) | 54 (53%) | 0 |
BMI, | ||
mean; ±SD | 27.7 ± 5.3 | 27.1 ± 4.2 |
Age at menarche | ||
mean ± SD | 12.3 ± 1.4 | 12.7 ± 1.3 |
Parity | ||
mean ± SD | 2.4 ± 1.6 | 3.6 ± 2.1 |
Nuliparous; n (%) | 18 (18%) | 1 (5%) |
Age at first pregnancy | ||
mean ± SD | 21 ± 5.4 | 23 ± 5.6 |
Breastfeeding; n (%) | 48/76 (63%) | 11/20 (55%) |
Contraceptive use; n (%) | 38/97 (39%) | 8/20 (40%) |
Smoking; n (%) | 17 (17%) | 7 (32%) |
Histology; n (%) | ||
Ductal | 80/90 (89%) | 18/22 (82%) |
Other | 10/90 (11%) | 4/22 (18%) |
Nuclear Grade; n (%) | ||
2 | 31/80 (39%) | 18/21 (86%) |
3 | 42/80 (53%) | 2/21 (10%) |
Stage; n (%) | ||
0 | 1/101 (1%) | 1. (0) |
I–II | 57/101 (56%) | 17/22 (77) |
III | 39/101 (39%) | 5/22 (23) |
IV | 4/101 (4%) | 0 (0) |
T; n (%) | ||
0–1 | 29/100 (29%) | 11/22 (50) |
2 | 37/100 (37%) | 7/22 (32) |
3 | 25/100 (25%) | 3/22 (14) |
4 | 9/100 (9%) | 1/22 (4) |
N; n (%) | ||
Positive | 59/99 (60%) | 12/22 (55%) |
IHC; n (%) | ||
ER (+) | 52/95 (55%) | 22/22 (100%) |
PR (+) | 47/95 (49%) | 21/22 (95%) |
HER (+) | 19/93 (20%) | 5/22 (23%) |
Triple negative | 30/93 (32%) | 0 (0%) |
Surgery type; n (%) | ||
Radical mastectomy | 80/99 (81%) | 10/22 (45%) |
Breast conservative | 18/99 (18%) | 12/22 (55%) |
Chemotherapy; n (%) | ||
Neoadjuvant | 28/100 (28%) | 4/22 (18%) |
Adjuvant | 62/100 (62%) | 15/22 (68%) |
Anthrac. based | 9/62 (15%) | 7/15 (40%) |
Anthrac/Taxane. | 45/62 (72%) | 6/15 (47%) |